Portal de Periódicos da CAPES

Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies

2005; Elsevier BV; Volume: 826; Issue: 1-2 Linguagem: Inglês

10.1016/j.jchromb.2005.09.010

1873-376X

Sylvie M. Guichard, Iain Mayer, Duncan I. Jodrell,

Cancer therapeutics and mechanisms

A reverse-phase high-performance liquid chromatography method with electrospray ionization and detection by mass spectrometry is described for the simultaneous determination of capecitabine, its intermediate metabolites (DFCR, DFUR) and the active metabolite 5-fluorouracil in mouse plasma, liver and human xenograft tumours. The method was also cross-validated in human plasma and human tumour for clinical application. The method has greater sensitivity than previously published methods with an equivalent accuracy and precision. It uses less biological material (plasma, tissue) and should therefore be applicable to biopsies in patients treated with capecitabine.